Imaging apolipoprotein AI in vivo
Författare
Summary, in English
Coronary disease risk increases inversely with high-density lipoprotein (HDL) level. The measurement of the biodistribution and clearance of HDL in vivo, however, has posed a technical challenge. This study presents an approach to the development of a lipoprotein MRI agent by linking gadolinium methanethiosulfonate (Gd[MTS-ADO3A]) to a selective cysteine mutation in position 55 of apo AI, the major protein of HDL. The contrast agent targets both liver and kidney, the sites of HDL catabolism, whereas the standard MRI contrast agent, gadolinium-diethylenetriaminepentaacetic acid-bismethylamide (GdDTPA-BMA, gadodiamide), enhances only the kidney image. Using a modified apolipoprotein AI to create an HDL contrast agent provides a new approach to investigate HDL biodistribution, metabolism and regulation in vivo. Copyright (C) 2011 John Wiley & Sons, Ltd.
Publiceringsår
2011
Språk
Engelska
Sidor
916-924
Publikation/Tidskrift/Serie
NMR in Biomedicine
Volym
24
Issue
7
Dokumenttyp
Artikel i tidskrift
Förlag
John Wiley & Sons Inc.
Ämne
- Radiology, Nuclear Medicine and Medical Imaging
Nyckelord
- NMR
- apolipoprotein
- HDL
- contrast agent
- MRI
- gadolinium
- cardiovascular risk
Status
Published
Forskningsgrupp
- Cellular Biomechanics
ISBN/ISSN/Övrigt
- ISSN: 0952-3480